1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. COVID-19

FebriDx for C-reactive protein and myxovirus resistance protein A testing

Medtech innovation briefing [MIB224] Published: 26 August 2020

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing
Download (PDF)

Advice

  • 3 NICE interactive flowcharts
    • Antimicrobial stewardship
    • Pneumonia
    • Self-limiting respiratory tract and ear infections – antibiotic prescribing
  • Next

NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing.

What are MIBs?

This advice updates and replaces medtech innovation briefing 114.


  • Next